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Background: The supply of controlled drugs is limited in the Far East, despite the prevalence of
health disorders that warrant their prescription. Reasons for this include strict regulatory frameworks,
limited financial resources, lack of appropriate training amongst the medical profession and fear
of addiction in both general practitioners and the wider population. Consequently, the weak opioid
tramadol has become the analgesic most frequently used in the region to treat moderate to severe pain.
Methods: To obtain a clearer picture of the current role and clinical use of tramadol in Southeast
Asia, pain specialists from 7 countries in the region were invited to participate in a survey, using
a questionnaire to gather information about their individual use and experience of this analgesic.
Results: Fifteen completed questionnaires were returned and the responses analyzed. Tramadol
is used to manage acute and chronic pain caused by a wide range of conditions. Almost all the
specialists treat moderate cancer pain with tramadol, and every one considers it to be significant
or highly significant in the treatment of moderate to severe non-cancer pain. The reasons for
choosing tramadol include efficacy, safety and tolerability, ready availability, reasonable cost,
multiple formulations and patient compliance. Its safety profile makes tramadol particularly
appropriate for use in elderly patients, outpatients, and for long-term treatment. The respondents
strongly agreed that tighter regulation of tramadol would reduce its medical availability and
adversely affect the quality of pain management. In some countries, there would no longer be
any appropriate medication for cancer pain or the long-term treatment of chronic pain.
Conclusions: In Southeast Asia, tramadol plays an important part in the pharmacological management of moderate to severe pain, and may be the only available treatment option. If it were to
become a controlled substance, the standard of pain management in the region would decline.
Keywords: tramadol, questionnaire, indications, efficacy, safety, controlled substance

Introduction
The unmet need for effective pain management remains high, particularly in low and
middle income countries. The World Health Organization (WHO) estimates that tens
of millions of people experience moderate to severe pain every year without access
to treatment, including 5.5 million with terminal cancer and a million with late stage
HIV infection.1 Research has shown that the availability of controlled opioid analgesics – such as morphine, hydrocodone and fentanyl – is very limited in many parts of
the world, including the Asian region.2–4
WHO Expert Committees advise the United Nations Commission on Narcotic
Drugs about pharmaceutical agents which should be designated controlled substances –
ie, have their manufacture, possession, or use regulated by a government – on the basis
of their individual therapeutic profiles and risk of abuse. Tramadol is a centrally acting
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analgesic combining both opioid and non-opioid mechanisms
of action that has been used to treat moderate to (moderately)
severe cancer and non-cancer pain for several decades.5 It has
been assessed several times by the WHO, but in each case
it was decided not to bring it under international control.6
Intercontinental Marketing Services Kilochem statistics
show that – except for non-steroidal anti-inflammatory
drugs (NSAIDs) and paracetamol – tramadol and tramadolcontaining products are the analgesics most often used in
clinical practice in a large group of Asian countries, with
increasing consumption over time (Figure 1).
To obtain a clearer picture of the role and clinical use of
tramadol in the Far East, pain specialists from 7 countries in
the region were invited to participate in a pilot survey, which
was drawn up in compliance with the Healthcare Professional Code of the European Federation of Pharmaceutical
Industries and Associations.7 A questionnaire was developed
to gather information about their use of tramadol, their
experience of its abuse potential in clinical practice, and
the influence of regulatory controls on medical availability.

(+)-tramadol and (−)-tramadol, which differ in their potencies at opioid receptors and monoamine uptake sites.8 Their
mechanisms of action are complementary and synergistic: the
(+)-enantiomer is a selective agonist at the µ-opioid receptor
and inhibits serotonin reuptake, while the (–)-enantiomer
mainly inhibits noradrenaline uptake.9,10 Furthermore, the
(+)-enantiomer is rapidly metabolized to mono-O-desmethyltramadol (M1 metabolite), which binds to the µ-opioid
receptor with an affinity two orders of magnitude higher than
that of the parent compound and ~1/10 that of morphine.9,11
Tramadol is extensively metabolized in the liver by Oand N-demethylation and by conjugation reactions to form
glucuronides and sulfates. The elimination of both tramadol
and its metabolites is predominantly via the kidneys, with
about 30% of the dose excreted in the urine as the parent
drug and the rest excreted as metabolites.12
The contraindications for treatment with tramadol include
acute respiratory depression, head injury, raised intracranial
pressure, acute intoxication and uncontrolled epilepsy.13

Tramadol

The questionnaire shown in Table 1 was emailed to 17 pain
specialists who expressed an interest in participating, in India
(3), Indonesia (3), Malaysia (2), Myanmar (2), Pakistan (3),

Tramadol [2-(dimethylaminomethyl)–1-(3-methoxyphenyl)
cyclohexanol] is a racemic 1:1 mixture of two enantiomers,
800
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Figure 1 Tramadol consumption in Asia compared to controlled opioids.
Notes: Consumption data from Quintiles IMS Kilochem 2015 (Bangladesh Retail, China, Hong Kong, India, Indonesia, Japan, Jordan Retail, Kazakhstan, Kuwait Retail, Lebanon
Retail, Malaysia, Pakistan Retail, Philippines, Saudi Arabia Retail, Singapore, South Korea, Sri Lanka Retail, Taiwan, Thailand, Turkey, UAE Retail, Vietnam); estimated PTD
calculation based on WHO ATC DDD of the respective substance, except for buprenorphine and fentanyl transdermal patches (units sold multiplied by wearing time).
Abbreviations: ATC, Anatomical Therapeutic Chemical classification system; DDD, defined daily dosage; IMS, Intercontinental Marketing Services; PTD, patient treatment
days; WHO, World Health Organization.
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Table 1 Questionnaire on the role of tramadol in pain management
With regards to your personal experiences with tramadol
1.

In which indications do you use tramadol?
Click here to enter text.

2.

What is the main reason for you to prescribe tramadol?
Click here to enter text.

3.

In your opinion, what are the main advantages/benefits of tramadol (in general, in comparison to other analgesics, eg, other opioids, or
NSAIDs)?
Click here to enter text.

4.

With regards to its safety and tolerability, how do you see tramadol compared to other opioids available in your country?
Click here to enter text.

5.

Based on your experiences, do you consider the abuse potential of tramadol lower than the abuse potential of other opioids?
Click here to enter text.
With regards to the use of tramadol in your country

6.

How do you rate the significance of tramadol for the treatment of the following pain indications/special patient groups in your country? Please
indicate for all listed indications/special patient groups: not significant (NS)/moderately significant (MS)/significant (S)/highly significant (HS)
For indications/special patient groups, you rated tramadol as “significant” or “highly significant”:
What are the main reasons for the high significance of tramadol in those indications/special patient groups?
Indication

Significance rating
(NS, MS, S, or HS)

If rating is significant or highly significant,
what are the main reasons?

Cancer pain

NS MS S HS

Click here to enter text.

Non-cancer pain

NS MS S HS

Click here to enter text.

Acute post-op pain

NS MS S HS

Click here to enter text.

Acute musculoskeletal pain

NS MS S HS

Click here to enter text.

Chronic low back pain

NS MS S HS

Click here to enter text.

Osteoarthritis

NS MS S HS

Click here to enter text.

Neuropathic pain

NS MS S HS

Click here to enter text.

Any other

NS MS S HS

Click here to enter text.

Pain treatment in adult patients

NS MS S HS

Click here to enter text.

Pain treatment in children

NS MS S HS

Click here to enter text.

Pain treatment in elderly patients

NS MS S HS

Click here to enter text.

Special patient groups

7.

Is tramadol used as an alternative to strong opioids in your country?
Click here to enter text.

8.

Are you aware of any official reports of misuse or abuse of tramadol in patients with chronic pain in your country?
Click here to enter text.

9.

If strong regulations (further controls/higher scheduling) regarding tramadol would be implemented in your country, which consequences do
you foresee in regard to:
• impact on medical availability of tramadol
 in the hospital
 in the outpatient setting
Click here to enter text.
• the treatment of patients with moderate to severe pain.
 Which treatment alternatives would you substitute for tramadol?
Click here to enter text.
 What would be the impact of this substitution in terms of efficacy, safety and convenience of the alternative treatment?
Click here to enter text.
• The quality of pain management in your country?
Click here to enter text.

10.

Is tramadol included in national guidelines? Please specify
Click here to enter text.

11.

Any other comments
Click here to enter text.

Abbreviation: NSAID, non-steroidal anti-inflammatory drugs.
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the Philippines (2) and Thailand (2). The questions were
formulated to identify their individual reasons for prescribing
tramadol and the conditions for which they prescribed it, as
well as the significance of tramadol in the management of
pain and the likely impact of tighter regulation on treatment
– both in hospital and in the community – in their own countries. A total of 15 completed questionnaires were returned
and the responses analyzed in November 2016.

for treating severe cancer pain, tramadol is often the only
option available.
Every one of the respondents considered tramadol to be
either significant or highly significant in the treatment of
moderate to severe non-cancer pain in their home country,
specifically mentioning acute indications such as labor pain,
postoperative and post-traumatic pain, and chronic indications such as low back pain and osteoarthritis. It is considered
an alternative to NSAIDs or strong opioids, particularly
suitable for elderly patients or those with poor liver and/or
renal function.18
The majority of respondents rated tramadol as significant or highly significant in the management of acute
postoperative pain and acute musculoskeletal pain. Specific
examples quoted were the combination of tramadol with
WHO step one analgesics or as an alternative to them, and
its use as a step-down analgesic from strong opioids following surgery.
Efficacy must be carefully balanced against safety when
long-term treatment is required for chronic conditions such
as osteoarthritis and chronic low back pain, and around
three-quarters of respondents regarded tramadol as being
significant or highly significant in managing these conditions.
Factors contributing to this rating included its efficacy in
mixed pain (ie, with nociceptive and neuropathic components), and its favorable benefit/risk ratio in prolonged use.
It was specifically noted that the safety issues associated with
NSAIDs often limit their use, particularly in chronic pain
patients and the elderly, so tramadol is frequently substituted
– an approach which is reflected in the current literature.19,20

Results
Indications for which tramadol is
prescribed
According to the experts, tramadol is used in the management
of moderate to severe acute and chronic pain caused by a
wide range of conditions. Their rating of the significance of
tramadol as a treatment option for various pain indications
is shown in Figure 2.
Almost all the specialists treat moderate cancer pain
with tramadol, a modality that is supported in the literature.13–15 Most of them rated it as significant or highly
significant in managing this condition. Important factors
influencing their choice of analgesic was tramadol’s efficacy in both nociceptive and neuropathic pain,16 which
often occur concurrently in cancer pain,17 its position as a
step two analgesic on the WHO “pain ladder”, and patients’
preference for it over low-dose strong opioids. Respondents
from India, Indonesia and Pakistan also stated that there is
limited or no availability of controlled opioid analgesics
in their countries. Although tramadol does not have the
same potency as strong opioid analgesics such as morphine
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Figure 2 Significance of tramadol in various acute and chronic pain indications.
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Over three-quarters of the specialists also rated the use
of tramadol in neuropathic pain as significant or highly
significant in their own country, mostly as a second line
option after drugs such as gabapentin. This is in line with
international recommendations.21
One respondent from India also prescribes tramadol for
fibromyalgia; both tramadol monotherapy and tramadol/
acetaminophen combination tablets have been shown to
reduce pain levels associated with this poorly understood
condition.22,23
In the case of specific patient groups, around three-
quarters of respondents considered the current use of tramadol to be significant or highly significant for adult and
elderly patients. The proportion was lower for children, at less
than one-third, primarily because the specialists have much
less clinical experience with pediatric patients. The reasons
given for the high significance accorded to tramadol in pain
management are listed in Table 2, and broadly mirror the
factors influencing the choice of analgesic outlined below.

Reasons for prescribing tramadol
Efficacy

The main reason for choosing tramadol to manage pain
in Asia – reflected by its high usage – is the wide-ranging
effectiveness resulting from its unique multimodal
mechanisms of action, which are well established.16,24–27
The responses confirm that tramadol effectively treats
both acute and chronic pain, as well as nociceptive and
neuropathic pain. This makes it particularly valuable for
managing pain states such as cancer pain and chronic
low back pain, which often have both nociceptive and
neuropathic components.28 In the case of chronic pain, its
risk-benefit profile in long-term use offers advantages over
other drugs, such as NSAIDs. Some respondents referred
specifically to the advantages of tramadol’s classification
Table 2 Reasons for the high significance of tramadol in pain
management
• Efficacy in moderate to severe nociceptive and neuropathic pain
• Good tolerability and safety profile compared to NSAIDs and strong
opioids, especially in elderly patients requiring long-term treatment
• Ready availability
• Multimodal mechanism of action, giving “opioid-sparing” effect
• Possibility of combination with other analgesics
• Availability of multiple formulations
• Lower risk of addiction than strong opioids
• Non-controlled prescription
• Easy to use
• Good patient compliance
Abbreviation: NSAIDs, non-steroidal anti-inflammatory drugs.

Journal of Pain Research 2018:11
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as a WHO step two compound, positioned after simple
analgesics (NSAIDs, c yclooxygenase-2 (COX‑2) inhibitors, paracetamol) and before the need for strong opioids.
In countries with limited or no access to strong opioids,
tramadol may be the only reliably available stronger analgesic for pain patients.

Safety and tolerability
Another decisive factor in the choice of tramadol is its safety
profile. It is frequently chosen in preference to NSAIDs,
which may cause renal and gastrointestinal impairment in
long-term use. Selective COX-2 inhibitors and especially
NSAIDs are associated with an elevated risk of severe gastrointestinal, renal and cardiovascular side effects,29–32 and the
risk increases with the duration of treatment. It is therefore
recommended that the lowest dose of these agents to control
symptoms should be prescribed for the shortest time.33 Tramadol is not associated with these side effects, and several
responders specifically cited its suitability for long-term use
in patients with chronic pain as a strong influence on their
choice of analgesic.
The side effect profile of strong opioids may include
nausea and vomiting, hypotension, tachycardia, respiratory
depression, abuse and neurological symptoms.34 While the
incidence of nausea and vomiting is not significantly different
between tramadol and strong opioids, especially in opioidnaïve patients and depending upon the route of administration, the general experience of the specialists is that tramadol
is well tolerated. Patients have fewer typical µ-opioid side
effects, particularly a reduced risk of respiratory depression,25
which has been confirmed by randomized clinical trials.35–37
This is in line with the observation from Vazzana et al that
the advantages of tramadol over other opioid medications are
its unique pharmacological profile, the lower incidence of
typical µ-opioid side effects and its lower abuse potential.38
Like many other opioids, tramadol can induce seizures.39
However, these occur mainly after administering tramadol
in doses which exceed the recommended upper limit or in
combination with medicinal products that lower the seizure
threshold. In patients with epilepsy or who are susceptible
to seizures it should be avoided. The concomitant use of
tramadol and serotonergic drugs may cause serotonin toxicity.
The respondents generally considered the abuse potential
of tramadol to be either lower or much lower than that of
strong opioids, and that it presents a lower risk of addiction. This is supported by experimental and clinical findings40–42 and reflects the current view of the WHO, which
concluded in its 2014 assessment that international control
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status is not warranted. Nevertheless, substances with a low
abuse potential may lead to a level of abuse under certain
circumstances, which may require targeted national measures
to address the specific problem. This has been the case in
Thailand, where the abuse of tramadol – mainly by adolescents – has led to targeted measures by the local authorities.
Overall, the experts concluded that the safety profile of
tramadol makes it particularly appropriate for use in elderly
patients, in the outpatient setting, and for longer periods of time.

Easy availability at reasonable cost
Tramadol is easily obtained on prescription in most Southeast
Asian countries and – as it is a generic analgesic – is relatively
inexpensive. Conversely, strong opioids are generally subject
to restrictive legal controls and may not even be available to
hospitals. The cost of morphine is generally low, but that of
newer opioids such as oxycodone, fentanyl and buprenorphine
– or specific formulations – is usually higher than that of tramadol. Also, supplies of strong opioids tend to be intermittent
and, unlike tramadol, only a limited range of formulations is
available. According to one respondent from India, tramadol
is the only non-NSAID analgesic obtainable in that country
in a formulation designed for oral administration.

Multiple formulations
The range of formulations available in the Far East includes
1) drops, capsules and tablets for oral use; and 2) solutions
for intramuscular, intravenous and subcutaneous injection.
Oral formulations are produced in both immediate release and
sustained release versions. Among the benefits of sustained
release are that it decreases peak plasma concentrations and
thereby reduces adverse effects, while the concomitant simpler
dosing regimen may improve patient compliance. In much
of the Far East a range of formulations is available, allowing
the clinician considerable scope to individualize treatment.

Patient compliance
Most respondents find that tramadol is well tolerated and one
specifically mentioned patient compliance as a factor in the
choice of analgesic. In some countries such as the Philippines
there is also a cultural influence; morphine has a stigma and
many patients believe they will become addicted to it, so compliance is poor. By contrast, tramadol is more readily accepted.

The potential impact of more stringent
controls on availability and treatment
Respondents strongly agreed that tighter regulation would
lead to a significant reduction in the medical availability
2572
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of tramadol, especially in the outpatient setting. In order to
compensate for this reduced availability, other analgesics
would be substituted; mainly NSAIDs, COX-2 inhibitors and
– in the hospital setting in a few countries – strong opioids.
If NSAIDs or COX-2 inhibitors were to be prescribed, their
lower efficacy means that fewer patients would achieve satisfactory pain relief, especially those with conditions which
have a neuropathic pain component. There would also be a
higher incidence of serious side effects on the gastrointestinal, renal and cardiovascular systems, especially over the
long term or in elderly patients. Other possible consequences
mentioned by respondents include the higher cost of alternative analgesics and a decline in patient compliance, owing
to patients’ fears of addiction to strong opioids and their
possible side effects.
All the respondents stated that the quality of pain management would be adversely affected, so many patients would
be left without appropriate treatment for moderate to severe
pain, especially in the outpatient setting. As strong opioids
are not readily available in several countries, including India
and Pakistan, some respondents foresee they would no longer have any appropriate medication for cancer pain or the
long-term treatment of chronic pain. The experts’ opinion
is supported by a survey, conducted by the International
Narcotics Control Board (INCB) in 2013,43 which confirmed
the negative impact of an international scheduling on the
availability of tramadol. In total, 72% of responders (33 of 46
countries) expressed concern that the introduction of control
measures would limit accessibility to tramadol and make
doctors more reluctant to prescribe it, which reflects past
experience of national tramadol controls leading to reduced
medical availability.43,44

Discussion
Tramadol has become the analgesic mostly frequently used
in the Far East to treat moderate to severe pain. It is readily
available and relatively cheap. This survey indicates that the
utilization of tramadol is based upon several factors:
• proven efficacy in treating various cancer and non-cancer
indications, supported by its inclusion in national/medical
society guidelines in 5 of the 7 countries surveyed;
• safety and tolerability compared to NSAIDs and strong
opioids;
• ease of storage and prescription compared to controlled
strong opioids;
• after major surgery, it can be used as a step-down analgesic following patient-controlled or epidural analgesia;
and
Journal of Pain Research 2018:11
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• it can be combined with NSAIDs, COX-2 inhibitors or
paracetamol to augment analgesia.
The experts’ responses clearly indicate that tramadol
is a valuable option to treat moderate to severe pain of
diverse origin. It is prescribed when non-opioids such as
paracetamol, NSAIDs and COX-2 inhibitors provide insufficient analgesia, are not tolerated, or are contra-indicated,
and where strong opioids are not justified or are unavailable.
This use is reflected by tramadol being included in a number
of national and international guidelines,45–47 and is in line
with its role in therapy as described in the international
literature.25,48,49
Chronic pain is an important public health issue. The Declaration of Montreal states that access to pain management
is a fundamental human right, and that all people with pain
should have access to appropriate assessment and treatment
without discrimination.50 However, studies have concluded
that 5.5 billion people (~83% of the world’s population) live
in countries with low to non-existent access to controlled
opioid analgesics, and only 460 million (7%) have adequate
access.1,2 The reasons for poor accessibility include strict
national regulations, lack of training in their use, and fear
of addiction among both health care professionals and the
general population. The United Nations’ 1961 Single Convention on Narcotic Drugs states the dual obligation to ensure
that controlled substances are available for medical purposes
and to protect populations against abuse and diversion.51 The
importance of making these substances available for those
who need them is continuously highlighted, eg, by international human rights organizations, the WHO, the INCB,
the World Health Assembly and regional intergovernmental
organizations.
In the Far East, the limited supply of controlled drugs is
illustrated by the fact that in 2005 the whole of Asia accounted
for only 3% of the world’s consumption of opioids, compared
to 67% for Europe.52 The situation has changed little since:
between 2001–2003 and 2011–2013 the worldwide consumption of opioids has more than doubled, yet in India it
increased by only 10% and in Myanmar it actually declined.53
A number of barriers to wider use in the region have been
identified; these include onerous regulatory frameworks,
restricted financial resources, and an absence of appropriate
training amongst the medical profession.53 In some countries
a fear of addiction among both general practitioners and the
wider population also acts as a disincentive.53,54 The disparity between the availability of opioid analgesics and the
prevalence of health disorders that warrant their prescription
remains a major cause of concern. Moreover, the prevalence
Journal of Pain Research 2018:11
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of certain pain syndromes (eg, joint pain, neuralgias) is projected to increase further in the coming decades, owing to the
rapidly increasing elderly population55; eg, Asia is projected
to see a >60% increase in the number of older people (60
years and over) between 2015 and 2030.56
If tramadol were to become a controlled substance, the
responses reveal a widely held belief that the medical availability of tramadol would be severely curtailed in the region,
especially in the outpatient setting, and the unmet need for
pain relief would increase significantly.
A key limitation of this survey is the small sample size,
but the responses from the disparate countries were highly
consistent over the range of questions.

Conclusions
In Southeast Asia, tramadol or tramadol-containing analgesics play an important part in the pharmacological management of moderate to severe pain. It provides a stronger
– and for many patients a safer – alternative to high doses
of NSAIDs or low doses of morphine, oxycodone or other
strong opioids. In addition, there are many situations where
tramadol is the only available option for treating moderate to
severe pain, accessible to inpatients and outpatients in regions
where controlled opioids are unobtainable. Pain specialists
in the region consider that access to tramadol would clearly
be reduced if it were to become a controlled substance. As a
direct consequence, the quality of pain management would
decline, particularly for patients who require longer term
treatment, and for some patients appropriate medication
would no longer be available.
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